Generalized Anxiety Disorder Clinical Trial
— GADOfficial title:
Efficacy of Massage and Light Touch Therapy for the Treatment of Generalized Anxiety Disorder
Verified date | July 2017 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There is an impressive and growing body of data suggesting that massage therapy is effective
in decreasing some symptoms of pathological conditions as well as facilitating growth,
reducing pain, increasing alertness, diminishing symptoms of depression and anxiety, and
enhancing immune function. Preliminary studies suggest that massage therapy decreases
symptoms of anxiety and depression, and lowers salivary cortisol levels in a wide array of
childhood and adult neuropsychiatric disorders including post-traumatic stress disorder,
attention-deficit-disorder hyperactivity, depression, bulimia and anorexia-nervosa.
Generalized Anxiety Disorder (GAD) is characterized by the presence of a constellation of
signs and symptoms for at least 6 months in duration, with some type of functional disability
or decrease in quality of life. The signs and symptoms of GAD include a myriad of somatic
symptoms including muscle tension, headaches, backaches, fatigue, restlessness, insomnia, as
well as psychological feelings of worry, anxiety, and feeling overwhelmed. Both
pharmacotherapy and psychotherapy are effective in decreasing the signs and symptoms of GAD.
Unfortunately, the vast majority of patients with GAD never receive adequate pharmacotherapy
or psychotherapy. Therefore, the development of a complementary and alternative therapy that
has demonstrated efficacy for GAD might be well received by patients.
This study's goals are to investigate the efficacy of Swedish massage therapy vs. light touch
therapy and better understand the biological effects of massage in patients with anxiety.
Qualified participants will be randomly assigned to one of two groups in which they will
receive Swedish massage therapy twice per week for 12 weeks or Light Touch therapy twice per
week for 6 weeks followed by Swedish massage therapy twice per week for the next 6 weeks. The
total length of the study is 13 weeks, which includes a screening visit that takes about 3
hours and two therapy visits per week for 12 weeks that last about 1 hour each. Blood and
urine will be collected at three of the visits. Compensation is up to $400 for completing the
entire study.
Status | Completed |
Enrollment | 40 |
Est. completion date | July 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Age 18 to 65 years old - Able to read and understand English - Medically healthy as demonstrated by a normal history and physical examination - Meet criteria for a primary diagnosis of current GAD as demonstrated by a structured clinical interview for DSM-IV (SCID), - HAM-A score of greater than 14 - Normal blood work and urinalysis (CBC, Renal, Hepatic, Tox Screen) Exclusion Criteria: - Individuals who lack a capacity to consent, or whose capacity to provide consent is questionable to the investigator - Current suicidal ideation (core of 3 or more on the HAM-D suicide item) - Current diagnosis of schizophrenia - Current diagnosis of bipolar disorder - Current diagnosis of borderline personality disorder - Comorbid secondary disorder diagnosis of OCD - Current illicit drug use - Excessive regular use of alcohol (more than two 5-oz glasses of wine or equivalents/day) or a history of binge drinking (more than 7 drinks/24 hour period) within the last six months - Regular or "PRN" psychotropic medication use - Current participation in psychotherapy or cognitive behavioral therapy - Pregnancy - Shift work schedule - Active dieting for weight loss - Active medical problems - Fibromyalgia (on daily medication) - Arthritis requiring daily meds and unable to abstain from meds for duration of study period |
Country | Name | City | State |
---|---|---|---|
United States | Emory University, Department of Psychiatry | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Center for Complementary and Integrative Health (NCCIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hamilton Anxiety Scale | 25 times over an average of 13 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 | |
Completed |
NCT00620776 -
Combined Treatment for Generalized Anxiety Disorder (GAD)
|
Phase 2 |